Pancreatic cancer is diagnosed at a late stage and has one of the highest cancer mortality rates in the United States, creating an urgent need for novel early detection tools. A candidate biomarker for use in early detection is the soluble MHC class I-related chain A (s-MICA) ligand, which pancreatic tumors shed to escape immune detection. The objective of this study was to define the association between s-MICA levels and pancreatic cancer, in a population-based case-control study. S-MICA was measured in 143 pancreatic cancer cases and 459 controls. Unconditional logistic regression was used to calculate odds ratio (OR) for pancreatic cancer and 95% confidence intervals (CI). There was a positive association between increasing s-MICA levels and pancreatic cancer: compared to the lowest tertile, the ORs for pancreatic cancer were 1.25 (95%CI: 0.75-2.07) and 2.10 (95%CI: 1.29-3.42) in the second and highest tertiles, respectively (P-trend = 0.02). Our study supports previous work demonstrating a positive association between plasma s-MICA levels and pancreatic cancer.
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| INTRODUCTION
Pancreatic cancer is one of the most lethal malignancies in the United States, with an overall 5-year survival rate of 8% and a median survival of 4-6 months, resulting in 40 000 deaths annually. 1 The majority of pancreatic cancer cases are diagnosed at an advanced disease stage, 2 due to lack of robust biomarkers. As a consequence, treatments such as surgery, radiation, and chemotherapy have little impact on patients'
survival and are mainly administered for palliative care. 3, 4 Hence, there is an urgent need for the development of novel early detection tools as population screening tests.
Pancreatic tumors secrete proteins that could be used for cancer screening. Specifically, these tumors shed proteins to evade detection by natural killer (NK) cells, which play a critical role in anti-tumor immunity. 5, 6 NK cells detect stress molecules on abnormal or infected cells through the interaction between an activating receptor (NKG2D) with its NKG2D ligands such as the MHC class-I related ligands MICA and MICB, as well as the UL16 binding protein (ULBP-16). 7, 8 Tumor cells release both MICA and MICB in soluble form (called s-MICA and s-MICB) by proteolytic shedding from the tumor cell surface by disentegrin and metalloproteinases (ADAM) 10 and 17. 6, 7, 9 In this study, we will focus on elucidating the role of s-MICA in pancreatic cancer, as genetic alterations in the MICA gene have been linked to pancreatic cancer development, making s-MICA a potential biomarker for early cancer detection. 6 The shedding of MICA inhibits NK cells in the tumor microenvironment, enabling tumor cells to avoid lysis by NK cells. 5, 6 Consistent with this mechanism, increased blood levels of s-MICA have been correlated with advanced cancer stage at diagnosis, metastasis, and worse prognosis in liver, [10] [11] [12] At the time of the in-person interviews, all participants were asked about demographics, cigarette smoking, physical activity, dietary and alcohol intake, and medical history, including the history of diabetes.
Subjects were also asked to donate a blood sample at the time of their in-person interview. Our analysis was restricted to Caucasians, who represented 96% of all study participants. After excluding participants without blood samples, a total of 163 cases and 542 controls were available for the current analysis (n = 705). Vital status for the study participants was ascertained through hospital records and records from the Minnesota Department of Health.
| s-MICA measurement
Thirty millimeters of venous blood were drawn from each consenting participant, frozen at −70°C and stored until analysis. S-MICA plasma levels were assessed using the Luminex Bead-based assay in the Cytokine Reference Laboratory (University of Minnesota). The detection limit for s-MICA was set at 2 pg/mL: 15% of the participants had s-MICA plasma levels below 2 pg/mL (20 out of 163) cases and 83 out of 542 controls). There was no association between case status and s-MICA levels below versus above the detection limit (P = 0.59); therefore, all subsequent analyses were restricted to those with s-MICA levels above the limit of detection (143 cases and 459 controls).
| Statistical analysis
The demographic, lifestyle, and other characteristics of cases and controls were compared using a t-test for continuous variables, and a The demographic and lifestyle characteristics of cases and controls are presented in Table 1 . As previously reported, participants with pancreatic cancer were more likely to smoke (15% vs 11%; P = 0.06), and be diabetic (32.9% vs 7.86%; P < 0.0001), but less likely to drink alcohol (47% vs 75%; P = 0.05) than control participants. 28 There were no significant differences in the distribution of participants based on sex, or age (P = 0.40 and P = 0.84, respectively).
In addition, we examined the plasma levels of s-MICA across participant demographic and lifestyle characteristics, according to case-control status. The median of s-MICA levels was higher in pancreatic cancer cases than in controls: 58.48 versus 43.07 pg/mL (P = < 0.05), and s-MICA levels were consistently higher in cases relative to controls across demographic and lifestyle characteristics (Supplementary Table S1 ). When cases and controls were examined separately, there were no notable differences in plasma s-MICA levels across strata of sex, smoking history and alcohol consumption in any group (P-value > 0.05 for all). Among cases, s-MICA levels were significantly higher in participants under 70 years old than in those above 70 years old. Among controls, s-MICA levels were significantly higher among participants with versus those without diabetes (P-value = 0.02) (Supplementary Table S1 ).
In the model adjusted for age and sex, ORs for pancreatic cancer were 1.29 (95%CI: 0.80-2.09) and 2.04 (95%CI: 1.29-3.24) in the second and third tertiles, respectively, compared to the first tertile (P-trend = 0.002; Table 2 ). In the model further adjusted for smoking history, alcohol consumption, and diabetes, the association between s-MICA and pancreatic cancer was similar: OR = 1.25 (0.75-2.07) and 2.10 (1.29-3.42) for the second and third tertiles, respectively, versus the first tertile (P-trend = 0.02).
In addition, we examined whether the s-MICA and pancreatic cancer association is modified by age, sex, smoking history, alcohol consumption, or diabetes. We found a statistically significant interaction between s-MICA and diabetes (P-interaction = 0.03).
Although positive associations were observed in both participants with diabetes (OR = 5.22, 95%CI: 1.08-25.15) and those without (OR = 1.88, 95%CI: 1.14-2.06) for the highest versus lowest tertiles of s-MICA levels, the s-MICA and pancreatic cancer association was stronger in diabetic participants (Table 3) (Table 3) . Finally, in a subset of 126 pancreatic cancer cases with known dates of death in our study, we did not observe any differences in survival for those with higher versus lower s-MICA levels (P-value for the log-rank test = 0.66) (Supplementary Fig. S1 ). reports, we observed a positive dose-response relationship between s-MICA levels and pancreatic cancer in the present study.
| DISCUSSION
The shedding of MICA into the blood leads to the surface depletion of MICA and down regulation of NKG2D receptor on NK cells. Furthermore, we reported that not only is s-MICA detected in the blood of cases, but also in healthy population controls, although at lower levels. This finding is consistent with a previous report of moderately increased s-MICA in benign conditions, such as nonmalignant tumors and chronic inflammation. 39 The reason for detecting s-MICA in the blood of controls in the present study is unclear, but its presence is likely indicative of increased cell turnover, so that the detected MICA reflects the protein in cell fragments. [35] [36] [37] [38] Importantly, the presence of s-MICA in healthy controls has implications regarding the suitability of this biomarker for cancer screening.
Another interesting finding in this study was that the positive association between s-MICA and pancreatic cancer was observed among male, but not female participants. This finding is in agreement with different mechanisms of immune evasion in men and women. For example, it has been reported that NKG2D expression varies by sex, 40 and this association further varies by age. [40] [41] [42] It is reasonable to hypothesize that differences in NKG2D expression and activity in men survival. 8, 23 However, Duan et al reported that tumors which did not express MICA were associated with better survival in the 3 years following tumor resection. 5 It is reasonable to assume that more tumors which express and shed MICA in its soluble form are better suited to escape immune surveillance. Given the limited sample size in all these studies, leading to an increased chance in false positive or false negative results, future studies will be needed to examine the association between s-MICA levels and patient survival in pancreatic cancer cases.
The strengths of this population-based study included a large number of cases and controls, and the ability to adjust for potential confounders. However, there are some limitations inherent in the present study. First, the response rate for both cases and control was less than 60%. Due to this low response rate, selection bias could have been introduced in the study, but it is unlikely that respondent differed significantly from non-respondents with regard to MICA levels among our controls. Second, although s-MICA levels were significantly associated with increased odds ratios of pancreatic cancer in both participants with and without diabetes, adjusting for diabetes could be an over adjustment in our statistical models, as diabetes may be on the causal pathway between s-MICA and pancreatic cancer. Pancreatic cancer risk is increased by 82% in those with diabetes versus those without, 43 and several studies have reported evidence that MICA gene polymorphisms are linked to diabetes. [44] [45] [46] [47] In addition, diabetes is often diagnosed at the time or after pancreatic cancer diagnosis and may be a consequence of pancreatic cancer rather than its cause.
However, our results indicate that the s-MICA and pancreatic cancer association was independent of diabetes status in our study. Finally, we did not have information about pancreatic cancer staging, and we were not able to compare s-MICA plasma levels to CA-19 plasma levels, a biomarker used for pancreatic cancer screening. Furthermore, we were not able to collect blood from pancreatic cancer patients with the most advanced disease, since they had died before they were enrolled into the study. This limited our power to make direct comparison between potential biomarkers for pancreatic cancer screening, and look at the association between s-MICA levels and pancreatic cancer survival in the present study.
In summary, our results support the hypothesis that plasma s-MICA levels are positively associated with pancreatic cancer. These results improve our understanding of this important protein in pancreatic cancer, which may be the key to elucidating the role of immune response by NK cells in pancreatic cancer. Our next step will be to correlate genetic variations in the highly polymorphic MICA gene with s-MICA levels, to clarify MICA's role in pancreatic carcinogenesis and explore immune-related associations between the MICA gene and pancreatic cancer.
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